PURPOSE: Chemotherapy can potentially enhance the activity of immune checkpoint inhibitors by promoting immune priming. The phase Ib/II JAVELIN Chemotherapy Medley trial (NCT03317496) evaluated first-line avelumab + concurrent chemotherapy in patients with advanced urothelial carcinoma or non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Avelumab 800 or 1,200 mg was administered continuously every 3 weeks with standard doses of cisplatin + gemcitabine in patients with urothelial carcinoma, or carboplatin + pemetrexed in patients with nonsquamous NSCLC. Dual primary endpoints were dose-limiting toxicity (DLT; phase Ib) and confirmed objective response (phase Ib/II). RESULTS: In phase Ib, urothelial carcinoma and NSCLC cohorts received avelumab 800 mg (n = 13 and n = 6, respectively) or 1,200 mg (n = 6 each) + chemotherapy. In evaluable patients with urothelial carcinoma treated with avelumab 800 or 1,200 mg + chemotherapy, DLT occurred in 1/12 (8.3%) and 1/6 (16.7%), respectively; no DLT occurred in the NSCLC cohort. In phase II, 35 additional patients with urothelial carcinoma received avelumab 1,200 mg + chemotherapy. Across all treated patients, safety profiles were similar irrespective of avelumab dose. Objective response rates (95% confidence internal) with avelumab 800 or 1,200 mg + chemotherapy, respectively, across phase Ib/II, were 53.8% (25.1-80.8) and 39.0% (24.2-55.5) in urothelial carcinoma, and 50.0% (11.8-88.2) and 33.3% (4.3-77.7) in NSCLC. CONCLUSIONS: Preliminary efficacy and safety findings with avelumab + chemotherapy in urothelial carcinoma and NSCLC were consistent with previous studies of similar combination regimens. Conclusions about clinical activity are limited by small patient numbers. SIGNIFICANCE: This phase Ib/II trial evaluated avelumab (immune checkpoint inhibitor) administered concurrently with standard first-line chemotherapy in patients with advanced urothelial carcinoma or advanced nonsquamous NSCLC without actionable mutations. Efficacy and safety appeared consistent with previous studies of similar combinations, although patient numbers were small.

AOU delle Marche Università Politecnica delle Marche Ancona Italy

Clinic Institute of Hematological and Oncological Diseases Hospital Clinic Barcelona Spain

Fundación Jiménez Díaz University Hospital Madrid Spain

General University Hospital Prague Prague Czech Republic

Hospital Universitario 12 de Octubre Madrid Spain

Instituto Valenciano de Oncología Valencia Spain

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola Italy

Kingston Health Sciences Centre Kingston Ontario Canada

National Institute of Oncology Budapest Hungary

NU Cancer Newcastle University Newcastle upon Tyne United Kingdom

Pfizer Milan Italy

Pfizer New York New York

Pfizer Paris France

Pfizer San Diego California

Pfizer San Francisco California

Royal Cornwall Hospital Treliske Truro United Kingdom

Sarah Cannon Research Institute HCA Healthcare London United Kingdom

St Vincent's Hospital Sydney Darlinghurst New South Wales Australia

Weston Park Hospital University of Sheffield Sheffield United Kingdom

Zobrazit více v PubMed

Bavencio (avelumab). Prescribing information. EMD Serono, Rockland, MA, USA; 2023.

Bavencio (avelumab). Summary of product characteristics. Merck Europe B.V., Amsterdam, Netherlands, an affiliate of Merck KGaA, Darmstadt, Germany; 2023.

Verschraegen CF, Jerusalem G, McClay EF, Iannotti N, Redfern CH, Bennouna J, et al. . Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. J Immunother Cancer 2020;8:e001064. PubMed PMC

Reck M, Bariesi F, Yang JC-H, Westeel V, Felip E, Özgüroğlu M, et al. . Avelumab vs chemotherapy for first-line treatment of advanced PD-L1+ NSCLC: primary analysis from JAVELIN Lung 100. J Thorac Oncol 2022;17:9. PubMed

NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. V3; 2023.

NCCN Clinical Practice Guidelines in Oncology. Bladder cancer. V3; 2023.

de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 2014;20:5384–91. PubMed PMC

Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy 2017;9:913–27. PubMed PMC

Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 2019;30:219–35. PubMed

Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013;39:74–88. PubMed

Keytruda (pembrolizumab). Prescribing information. Merck & Co., Kenilworth, NJ, USA; 2022.

Opdivo (nivolumab). Prescribing information. Bristol Myers Squibb Company; 2022.

Tecentriq (atezolizumab). Prescribing information. Genentech; 2021.

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, et al. . Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:931–45. PubMed

Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. . Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020;395:1547–57. PubMed

Bamias A, Davis ID, Galsky MD, Arija JÁA, Kikuchi E, Grande E, et al. . Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study. J Clin Oncol 41: 6s, 2023. (suppl; abstr LBA441).

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. . Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383:1218–30. PubMed

Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ullén A, et al. . Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up. J Clin Oncol 2023;41:3486–92. PubMed PMC

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. . Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:244–58. PubMed

Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. . European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021;79:82–104. PubMed

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. . Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1103–15. PubMed PMC

Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, et al. . Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer 2020;8:e001246. PubMed PMC

D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, et al. . Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer 2020;8:e000674. PubMed PMC

D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, et al. . First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer 2021;9:e002646. PubMed PMC

Novakovic AM, Wilkins JJ, Dai H, Wade JR, Neuteboom B, Brar S, et al. . Changing body weight-based dosing to a flat dose for avelumab in metastatic merkel cell and advanced urothelial carcinoma. Clin Pharmacol Ther 2020;107:588–96. PubMed PMC

Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, et al. . Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 2017;18:587–98. PubMed PMC

Herrera AF, Burton C, Radford J, Miall F, Townsend W, Santoro A, et al. . Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. Blood Adv 2021;5:3387–96. PubMed PMC

Platinol (cisplatin). Prescribing information. Bristol-Myers Squibb; 2019.

Gemzar (gemcitabine). Prescribing information. Eli Lilly; 2019.

Alimta (pemetrexed disodium). Prescribing information. Eagle Pharmaceuticals, Inc; 2022.

Paraplatin (carboplatin). Prescribing information. Pfizer; 2022.

Zajac M, Boothman AM, Ben Y, Gupta A, Jin X, Mistry A, et al. . Analytical validation and clinical utility of an immunohistochemical programmed death ligand-1 diagnostic assay and combined tumor and immune cell scoring algorithm for durvalumab in urothelial carcinoma. Arch Pathol Lab Med 2019;143:722–31. PubMed

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. . Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497–508. PubMed PMC

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. . Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379:2040–51. PubMed

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. . Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078–92. PubMed

Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. . Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol 2021;16:653–64. PubMed

Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, et al. . Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 2022;28:2374–80. PubMed PMC

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2020;21:1574–88. PubMed

Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJ, Ching KA, et al. . Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat Med 2021;27:2200–11. PubMed

Powles TB, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. . LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol 2023;34:S1340.

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03317496